The FDA has approved a gemcitabine intravesical system for Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS), either with or without ...

NASHVILLE, Tenn.--(BUSINESS WIRE)--Virtuoso Surgical Inc., a Nashville-based surgical robotics company, today announced the first-in-human use of its Virtuoso system, ushering in a new era of ...

Although bladder cancer ranks as the sixth most common cancer in the United States, with approximately 85,000 new cases diagnosed each year, it continues to receive limited awareness, advocacy, and ...

(Bloomberg) -- Johnson & Johnson said it won US approval for a tiny drug-delivery system to treat bladder cancer, a first-of-its kind product the company expects to bring in blockbuster revenue.

A new drug-releasing system, TAR-200, eliminated tumors in 82% of patients in a phase 2 clinical trial for individuals with high-risk non-muscle-invasive bladder cancer whose cancer had previously ...

Please provide your email address to receive an email when new articles are posted on . Most patients with non-muscle-invasive bladder cancer who received TAR-200 with gemcitabine achieved complete ...